Your browser doesn't support javascript.
loading
Prediction of human pharmacokinetics of long half-life compounds using chimeric mice with humanised liver.
Miyamoto, Maki; Iwasaki, Shinji; Chisaki, Ikumi; Nakagawa, Sayaka; Amano, Nobuyuki; Kosugi, Yohei; Hirabayashi, Hideki.
Afiliação
  • Miyamoto M; Drug Metabolism and Pharmacokinetics Research Laboratories, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited , Fujisawa , Kanagawa , Japan.
  • Iwasaki S; Drug Metabolism and Pharmacokinetics Research Laboratories, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited , Fujisawa , Kanagawa , Japan.
  • Chisaki I; Drug Metabolism and Pharmacokinetics Research Laboratories, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited , Fujisawa , Kanagawa , Japan.
  • Nakagawa S; Drug Metabolism and Pharmacokinetics Research Laboratories, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited , Fujisawa , Kanagawa , Japan.
  • Amano N; Drug Metabolism and Pharmacokinetics Research Laboratories, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited , Fujisawa , Kanagawa , Japan.
  • Kosugi Y; Drug Metabolism and Pharmacokinetics Research Laboratories, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited , Fujisawa , Kanagawa , Japan.
  • Hirabayashi H; Drug Metabolism and Pharmacokinetics Research Laboratories, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited , Fujisawa , Kanagawa , Japan.
Xenobiotica ; 49(12): 1379-1387, 2019 Dec.
Article em En | MEDLINE | ID: mdl-30744481
ABSTRACT
1. The prediction of human pharmacokinetic (PK) parameters is an important theme to select drug candidates from preclinical studies. It is essential to improve the prediction accuracy of compound half-life (t1/2) in humans. In this study, the predictability of t1/2 in humans using PXB mice®, chimeric mice with humanised liver, was assessed using 14 compounds showing long t1/2 in humans. 2. After intravenous administration of the compounds to PXB mice, the plasma concentration-time profiles were fitted using one- or two-compartment models and the human clearance (CLt) and distribution volume (Vdss) were predicted from single-species scaling. Using the obtained parameters, the t1/2 in humans was predicted. Using PXB mice, the predicted t1/2 values of 71.4% of the compounds were within two-fold of the actual values. Meanwhile, based on predictions using SCID mice, the host strain of the PXB mice, only 7.1% of tested compounds were within two-fold. 3. In conclusion, we demonstrated the novel utility of PXB mice for human PK predictions of compounds having long t1/2 in humans.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Farmacocinética / Fígado Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Animals / Humans / Male Idioma: En Revista: Xenobiotica Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Japão

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Farmacocinética / Fígado Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Animals / Humans / Male Idioma: En Revista: Xenobiotica Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Japão